DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
\- thyroid cancer diagnosis
Exclusion Criteria:
* patients unable to sign informed consent
Primary outcome measure(s)
Dynamic risk stratification — one year from the primary treatment impact of the different variables on the DRS
Dynamic risk stratification — five years from the primary treatment impact of the different variables on the DRS
Dynamic risk stratification — ten years from the primary treatment impact of the different variables on the DRS
Progression-free survival — one year from the primary treatment impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer
Progression-free survival — five years from the primary treatment impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer
Progression-free survival — ten years from the primary treatment impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer
Overall survival — one year from the primary treatment impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer
Overall survival — five years from the primary treatment impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer
Overall survival — ten years from the primary treatment impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
